Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1972 May;11(1):21–29.

Decreased synthesis of the third component of complement (C3) in hypocomplementenic systemic lupus erythematosus

A J Sliwinski, N J Zvaifler
PMCID: PMC1553672  PMID: 5038771

Abstract

Metabolism of the third component of complement (C3) was evaluated in eight normal subjects and nine patients with systemic lupus erythematosus (SLE). Six of the nine patients with SLE were hypocomplementemic; four of these had active renal disease. In the eight normals, the half-life survival (T 1/2) was 49–66 hr, the catabolic rate (Km) was 1·8 to 3·5% of plasma pool/hr, and the synthetic rate (Ks) 0·89–2·0 mg/kg/hr. Two SLE patients with normal C3 had a normal T 1/2, Km and Ks; one with increased C3 had a shortened T 1/2 and a high Km and Ks. Three patients with untreated SLE and depressed C3 had T 1/2 of 21 hr, 37 hr, and 69 hr, Km of 5·3%, 3·5% and 1·6% with Ks of 0·48, 0·95 and 0·23 mg/kg/hr, respectively. Three other patients with low C3 levels taking corticosteroids had normal Km but depressed Ks. Three patients were restudied after prednisone therapy. All had an increased C3 and Ks, two had an increase in T 1/2 and a decrease in Km, while one did not change T 1/2 or Km. In summary, five of six SLE patients with low C3 had a depressed Ks. The lowest value of C3 was generally associated with the lowest Ks. Depressed Ks occurred in patients with or without renal disease. These results indicate that static measurements of C3 do not quantify the degree of C3 utilization. The major determinant of the low C3 observed in this study of SLE was decreased synthesis of C3.

Full text

PDF
21

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alper C. A., Rosen F. S. Alper CA, Rosen FS: Studies of the in vivo behavior of human C'3 in normal subjects and patients. J Clin Invest. 1967 Dec;46(12):2021–2034. doi: 10.1172/JCI105691. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Carpenter C. B., Ruddy S., Shehadeh I. H., Müller-Eberhard H. J., Merrill J. P., Austen K. F. Complement metabolism in man: hypercatabolism of the fourth (C4) and third (C3) components in patients with renal allograft rejection and hereditary, angioedema (HAE). J Clin Invest. 1969 Aug;48(8):1495–1505. doi: 10.1172/JCI106116. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Gruber J., Wright G. G. Iodine-131 labeling of purified microbial antigens by microdiffusion. Proc Soc Exp Biol Med. 1967 Oct;126(1):282–284. doi: 10.3181/00379727-126-32425. [DOI] [PubMed] [Google Scholar]
  4. KENT J. F., FIFE E. H., Jr Precise standardization of reagents for complement fixation. Am J Trop Med Hyg. 1963 Jan;12:103–116. doi: 10.4269/ajtmh.1963.12.103. [DOI] [PubMed] [Google Scholar]
  5. Koffler D., Carr R. I., Agnello V., Fiezi T., Kunkel H. G. Antibodies to polynucleotides: distribution in human serums. Science. 1969 Dec 26;166(3913):1648–1649. doi: 10.1126/science.166.3913.1648. [DOI] [PubMed] [Google Scholar]
  6. MORSE J. H., MULLER-EBERHARD H. J., KUNKEL H. G. Anti-nuclear factors and serum complement in systemic lupus erythematosus. Bull N Y Acad Med. 1962 Oct;38:641–651. [PMC free article] [PubMed] [Google Scholar]
  7. NILSSON U. R., MUELLER-EBERHARD H. J. ISOLATION OF BETA IF-GLOBULIN FROM HUMAN SERUM AND ITS CHARACTERIZATION AS THE FIFTH COMPONENT OF COMPLEMENT. J Exp Med. 1965 Aug 1;122:277–298. doi: 10.1084/jem.122.2.277. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Petz L. D., Fink D. J., Letsky E. A., Fudenberg H. H., Müller-Eberhard J. In vivo metabolism of complement. I. Metabolism of the third component (C'3) in acquired hemolytic anemia. J Clin Invest. 1969 Nov;47(11):2469–2484. doi: 10.1172/JCI105929. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Schur P. H., Sandson J. Immunologic factors and clinical activity in systemic lupus erythematosus. N Engl J Med. 1968 Mar 7;278(10):533–538. doi: 10.1056/NEJM196803072781004. [DOI] [PubMed] [Google Scholar]
  10. Ward P. A., Zvaifler N. J. Complement-derived leukotactic factors in inflammatory synovial fluids of humans. J Clin Invest. 1971 Mar;50(3):606–616. doi: 10.1172/JCI106531. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Zvaifler N. J. Breakdown products of C 3 in human synovial fluids. J Clin Invest. 1969 Aug;48(8):1532–1542. doi: 10.1172/JCI106119. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Zvaifler N. J., Martinez M. M. Antinuclear factors and chronic articular inflammation. Clin Exp Immunol. 1971 Feb;8(2):271–278. [PMC free article] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES